A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael Friedlander, Kidong Kim, David SP Tan
International Journal of Gynecologic Cancer Aug 2020, 30 (8) 1239-1242; DOI: 10.1136/ijgc-2020-001604
